• Lexicon Pharmaceuticals Inc., of The Woodlands, Texas, reported positive, topline data from its recently completed Phase II study of LX1032 (telotristat etiprate) in carcinoid syndrome. Five subjects receiving LX1032 achieved reductions of at least 30 percent in the number of bowel movements per day for two weeks or more; six reported adequate relief of symptoms; and nine had a complete biochemical response defined as a reduction of at least 50 percent in urinary 5-HIAA. No patients on placebo experienced a clinical response, adequate symptom relief or a biochemical response during the randomized, double-blind U.S. study that enrolled 23 patients. The company also reported preliminary data from an ongoing, open-label, single-arm study of telotristat etiprate in Europe. To date, five out of six patients with refractory carcinoid syndrome have experienced sustained reductions of at least 30 percent in bowel movement frequency when treated with LX1032.